ReviewBlood cancer journal2021
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.
Review in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global epidemiology of amyloid light-chain amyloidosis.Orphanet journal of rare diseases · 2022Pooled it
- Article
- Association Between Common Variable Immunodeficiency and Pulmonary Amyloidosis: Review.Journal of clinical medicine · 2026Review
- A retrospective real-world study assessing diagnostic pattern of light-chain amyloidosis in Japan based on data from the medical data vision claims database.Therapeutic advances in hematology · 2026Article
- Amyloid Light Chain Proteins in Cardiovascular Disease: Pathogenesis and Emerging Therapies for Cardiac Amyloidosis.Pharmaceutical research · 2025Review
- Multimodality Imaging in Monoclonal Gammopathy of Undetermined Significance and ATTR Wild-Type Cardiac Amyloidosis.Life (Basel, Switzerland) · 2025Article
- Clonal Hematopoietic Mutations in Plasma Cell Disorders: Clinical Subgroups and Shared Pathogenesis.Genomics, proteomics & bioinformatics · 2025Article
- Localized Amyloidosis of the Oral Cavity: A Rare Clinical Entity.Clinical case reports · 2025Article
- Immunoglobulin heavy/light chain assay in the diagnosis, monitoring and follow-up of renal AL amyloidosis patients at different disease stages.Annals of hematology · 2025Article
- Spontaneous Hepatic Hemorrhage as a Rare Presentation of Amyloid Light Chain (AL) Amyloidosis: A Case Report.Cureus · 2025Article
- Age-related TFEB downregulation in proximal tubules causes systemic metabolic disorders and occasional apolipoprotein A4-related amyloidosis.JCI insight · 2024Article
- The myocardial function index (MFI): An integrated measure of cardiac function in AL-cardiomyopathy.International journal of cardiology. Heart & vasculature · 2024Article
- Using machine learning approaches to develop a fast and easy-to-perform diagnostic tool for patients with light chain amyloidosis: a retrospective real-world study.Annals of hematology · 2024Article
- Healthcare resource utilisation and costs associated with AL amyloidosis: a retrospective matched cohort study.Scientific reports · 2024Article
- Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group.Advances in therapy · 2023Review
- Unveiling the Effects of Copper Ions in the Aggregation of Amyloidogenic Proteins.Molecules (Basel, Switzerland) · 2023Review
- Characterization of Plasma SDS-Protein Aggregation Profile of Patients with Heart Failure with Preserved Ejection Fraction.Journal of cardiovascular translational research · 2023Article
- Cardiac amyloidosis: state-of-the-art review.Journal of geriatric cardiology : JGC · 2023Article
- Amyloidosis: a case series and review of the literature.Journal of medical case reports · 2023Review
- Detection and Diagnosis of Cardiac Amyloidosis in Egypt.Cardiology and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients presenting with these symptoms. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Herein we provide a review of established and investigational treatments for patients with AL amyloidosis and provide algorithms for workup and management of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.